Multicenter phase II trial of first-line docetaxel/gemcitabine in advanced breast cancer pretreated with adjuvant anthracyclines

Patrizia Vici, Francesco Giotta, Luigi Di Lauro, Mario Brandi, Vittorio Gebbia, Paolo Foggi, Vito Lorusso, Carlo Vitucci, Domenico Sergi, Silvia Ileana Fattoruso, Diana Giannarelli, Giuditta Viola, Serena Corsetti, Giuseppe Colucci, Massimo Lopez

Research output: Contribution to journalArticlepeer-review

Abstract

The aim of this study was to evaluate activity and tolerability of docetaxel-gemcitabine combination as first-line treatment in patients with metastatic breast cancer previously treated with adjuvant anthracydines. Patients and Methods: Sixty-eight women received gemcitabine 1,000 mg/m 2 as 30-minute infusion on days 1 and 8, and docetaxel 80 mg/m 2 as 1-hour infusion on day 8, with cycles repeated every 3 weeks. Results: Objective responses were observed in 32 out of 68 evaluable patients (45%; 95% confidence interval, 35.2-58.8%). Responses were 44%, 42%, 49% in soft tissue, bone and visceral lesions, respectively, 50%/52% in HER2-positive/-negative tumors, and 50% in both ER- positive/-negative tumors. Median time to progression and overall survival were 6 and 16 months, respectively. Treatment was usually well tolerated, with grade 3-4 neutropenia in 32%-7% of the patients, and neutropenic fever, grade 3 vomiting, mucositis and peripheral neurotoxicity in 3% of the patients. Conclusion: Gemcitabine-docetaxel combination is effective and well tolerated as first-line treatment in advanced breast cancer previously treated with adjuvant anthracyclines.

Original languageEnglish
Pages (from-to)1841-1845
Number of pages5
JournalAnticancer Research
Volume29
Issue number5
Publication statusPublished - May 2009

Keywords

  • Advanced breast cancer
  • Docetaxel
  • Gemcitabine

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Multicenter phase II trial of first-line docetaxel/gemcitabine in advanced breast cancer pretreated with adjuvant anthracyclines'. Together they form a unique fingerprint.

Cite this